PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU

Company Developments - Insulet made its Omnipod 5 AID system compatible with Abbott's FreeStyle Libre 2 Plus CGM sensor in the United States in November 2024 [1] - The company released the Omnipod 5 App for iPhone in the United States in October 2024, featuring a Custom Foods feature for carbohydrate tracking [1] - Insulet expanded the commercial availability of Omnipod 5 to five more countries: Italy, Denmark, Finland, Norway, and Sweden, with compatibility for both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 CGM sensors [5] - Omnipod 5 is recognized as the number one insulin pump for new users in Europe and the top prescribed AID system in the United States [7] - Omnipod 5 is the first tubeless AID system for individuals aged two years and older with type 1 diabetes, simplifying diabetes management with SmartAdjust technology [9] - Omnipod 5 demonstrated strong clinical results in the United States since its 2022 launch and expanded to the UK, Germany, France, and the Netherlands by June 2024 [10] Stock Performance and Market Sentiment - PODD shares rose 0.7% to $270 in after-market trading following the announcement on Jan 14 [2] - Insulet's shares have risen 33.7$18.80 billion and is expected to see a 17.1% earnings increase in 2024 with a 21.2% revenue improvement [6] - Insulet delivered an average earnings beat of 52.4% over the trailing four quarters [6] Industry Prospects - The global diabetes devices market was valued at $30.31 billion in 2023 and is expected to grow at a CAGR of 7.5% through 2030 [3] - Market growth is driven by increasing diabetes prevalence, rising usage of insulin-delivery devices, and high obesity rates [3] - The industry is characterized by high innovation, focusing on accurate and efficient diagnosis and treatment solutions [3] Competitor Performance - Omnicell (OMCL) has an estimated earnings growth rate of 72.7% for Q4 2024 and delivered an average earnings surprise of 121.74% over the trailing four quarters [8] - Veracyte (VCYT) delivered an average earnings surprise of 520.58% over the trailing four quarters, with shares rising 49.2% in the past year [11] - ResMed (RMD) has an estimated growth rate of 21.1% for 2025 and delivered an average earnings surprise of 6.41% over the trailing four quarters [11]